Prognostic Factors in Children with HLH Investigated
|
By LabMedica International staff writers Posted on 27 Oct 2016 |

Image: A photomicrograph of a bone marrow showing stromal macrophages containing numerous red blood cells in their cytoplasm from a patient with hemophagocytic lymphohistiocytosis (Photo courtesy of Nephron).
Hemophagocytic lymphohistiocytosis (HLH) is a rare disease characterized by a rapidly fatal hematological disorder usually associated with malignancies and severe infections and it presents with prolonged high fever that could not be controlled by antibiotics.
Other manifestations of HLH are hepatosplenomegaly, cytopenia, widespread infiltration with lymphocytes, and benign-looking histiocytes with hemophagocytosis in the bone marrow, liver, spleen, or lymph nodes. Early diagnosis and combined treatment can effectively control this life-threatening disease.
Scientists at the Guangdong Medical College (Shenzhen, People’s Republic of China) carried out a retrospective analysis on HLH from January 1, 2000, to November 30, 2013. Of the 56 pediatric patients, 35 were boys and 21 were girls with a median age of 4.5 years (range: four months to 12 years) at the onset of HLH. The median duration before diagnosis of HLH was 1.5 weeks (range: one week to six weeks). The most common clinical symptoms observed were fever (100%), hepatomegaly or splenomegaly (95.24%), and pancytopenia (100%).
The team found that characteristic laboratory values presented with increased ferritin (64.29%), triglycerides (78.6%), transaminases (81%), bilirubin (67.5%), lactate dehydrogenase (95.2%), and decreased fibrinogen (61.9%), sodium (40.5%), and potassium (30.9%). Bone marrow aspiration showed hemophagocytosis in 48 cases (85.7%). Among the clinical and laboratory features analyzed, high lactate dehydrogenase (LDH) of greater than 2,000 U/L, high bilirubin of greater than 2 mg/mL, and younger age less than 2 years old at the time of diagnosis indicated worst outcome.
Anemia was observed in 39 patients (five cases with hemoglobin level less than 90 g/L, 27 cases less than 60–89 g/L, seven cases less than 30–59 g/L), neutropenia (neutrophil count less than 1.5×109/L) in 28 patients (22 cases less than 0.5–1.0×109/L, and five cases less than 0.5×109/L, and thrombocytopenia (platelet count less than 100×109/L) in 35 patients (33 cases with platelet count less than 20–99×109/L and two cases with platelet count less than 20×109/L). Examination of bone marrow aspiration showed hemophagocytosis in 48 (85.7%) patients.
The authors concluded that the etiology of HLH is complicated and early diagnosis is difficult. The level of LDH and bilirubin may predict the severity of HLH and depending on the clinical presentation, individualized therapy is needed for different patients. The study was published on October 11, 2016, in the Journal of Blood Medicine.
Related Links:
Guangdong Medical College
Other manifestations of HLH are hepatosplenomegaly, cytopenia, widespread infiltration with lymphocytes, and benign-looking histiocytes with hemophagocytosis in the bone marrow, liver, spleen, or lymph nodes. Early diagnosis and combined treatment can effectively control this life-threatening disease.
Scientists at the Guangdong Medical College (Shenzhen, People’s Republic of China) carried out a retrospective analysis on HLH from January 1, 2000, to November 30, 2013. Of the 56 pediatric patients, 35 were boys and 21 were girls with a median age of 4.5 years (range: four months to 12 years) at the onset of HLH. The median duration before diagnosis of HLH was 1.5 weeks (range: one week to six weeks). The most common clinical symptoms observed were fever (100%), hepatomegaly or splenomegaly (95.24%), and pancytopenia (100%).
The team found that characteristic laboratory values presented with increased ferritin (64.29%), triglycerides (78.6%), transaminases (81%), bilirubin (67.5%), lactate dehydrogenase (95.2%), and decreased fibrinogen (61.9%), sodium (40.5%), and potassium (30.9%). Bone marrow aspiration showed hemophagocytosis in 48 cases (85.7%). Among the clinical and laboratory features analyzed, high lactate dehydrogenase (LDH) of greater than 2,000 U/L, high bilirubin of greater than 2 mg/mL, and younger age less than 2 years old at the time of diagnosis indicated worst outcome.
Anemia was observed in 39 patients (five cases with hemoglobin level less than 90 g/L, 27 cases less than 60–89 g/L, seven cases less than 30–59 g/L), neutropenia (neutrophil count less than 1.5×109/L) in 28 patients (22 cases less than 0.5–1.0×109/L, and five cases less than 0.5×109/L, and thrombocytopenia (platelet count less than 100×109/L) in 35 patients (33 cases with platelet count less than 20–99×109/L and two cases with platelet count less than 20×109/L). Examination of bone marrow aspiration showed hemophagocytosis in 48 (85.7%) patients.
The authors concluded that the etiology of HLH is complicated and early diagnosis is difficult. The level of LDH and bilirubin may predict the severity of HLH and depending on the clinical presentation, individualized therapy is needed for different patients. The study was published on October 11, 2016, in the Journal of Blood Medicine.
Related Links:
Guangdong Medical College
Latest Hematology News
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Channels
Clinical Chemistry
view channel
Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
Diagnosing the cause of cognitive decline in adults over 80 is challenging because multiple comorbidities can blur early clinical presentations. As a result, memory complaints are often attributed to normal... Read more
ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
Laboratory medicine increasingly intersects with gender-affirming care, where hormone therapy and rigid health record fields can complicate the interpretation of routine tests. Without appropriate clinical... Read moreMolecular Diagnostics
view channel
WHO Adds First Bundibugyo Ebola Molecular Test to Emergency Use Listing
Ebola disease caused by Bundibugyo virus is a severe, often life-threatening illness that spreads through contact with infected bodily fluids. Rapid confirmation of infection is critical for early care,... Read more
Study Supports Earlier Genetic Testing for Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancers may go undetected in at-risk relatives until standard screening begins, narrowing the window for prevention. Earlier identification of pathogenic variants can inform... Read moreImmunology
view channel
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Genomic surveillance is essential for detecting viral variants before they spread widely, yet many public health systems face high costs, uneven capacity, and computational barriers. Existing analytic... Read more
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read morePathology
view channel
EBV Status Helps Predict Survival in Primary CNS Lymphoma
Primary central nervous system lymphoma is a rare malignancy in which tumors arise in the brain and, less often, the spinal cord, eyes, or cerebrospinal fluid. Outcomes are especially variable when the... Read more
AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
Immunotherapy has transformed care for select malignancies, yet predicting which patients with rare cancers are most likely to benefit remains challenging. Clinicians often have only limited biomarkers... Read moreTechnology
view channel
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more








